Cerus Corp
CERS1.710USD
+0.300+21.28%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
327.62MMarket Cap
LossP/E TTM
More Details of Cerus Corp Company
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Cerus Corp Info
Ticker SymbolCERS
Company nameCerus Corp
IPO dateJan 31, 1997
CEOMr. William M. (Obi) Greenman
Number of employees281
Security typeOrdinary Share
Fiscal year-endJan 31
Address1220 Concord Avenue
CityCONCORD
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94520
Phone19252886000
Websitehttps://www.cerus.com/
Ticker SymbolCERS
IPO dateJan 31, 1997
CEOMr. William M. (Obi) Greenman
Company Executives of Cerus Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
304.17K
+24.57%
Mr. Kevin Dennis Green, CPA
Mr. Kevin Dennis Green, CPA
Chief Financial Officer, Vice President - Finance
Chief Financial Officer, Vice President - Finance
289.70K
-64.05%
Ms. Ann Lucena
Ms. Ann Lucena
Independent Director
Independent Director
182.05K
+49.16%
Dr. Hua Shan, M.D., Ph.D.
Dr. Hua Shan, M.D., Ph.D.
Independent Director
Independent Director
131.10K
+84.39%
Mr. William M. (Obi) Greenman
Mr. William M. (Obi) Greenman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Jami K. Nachtsheim ,
Jami K. Nachtsheim ,
Independent Director
Independent Director
--
--
Mr. Dean A. Gregory
Mr. Dean A. Gregory
Director
Director
--
--
Dr. Frank R. Witney, Ph.D.
Dr. Frank R. Witney, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Richard J. Benjamin, Ph.D.
Dr. Richard J. Benjamin, Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Timothy L. (Tim) Moore
Mr. Timothy L. (Tim) Moore
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
304.17K
+24.57%
Mr. Kevin Dennis Green, CPA
Mr. Kevin Dennis Green, CPA
Chief Financial Officer, Vice President - Finance
Chief Financial Officer, Vice President - Finance
289.70K
-64.05%
Ms. Ann Lucena
Ms. Ann Lucena
Independent Director
Independent Director
182.05K
+49.16%
Dr. Hua Shan, M.D., Ph.D.
Dr. Hua Shan, M.D., Ph.D.
Independent Director
Independent Director
131.10K
+84.39%
Mr. William M. (Obi) Greenman
Mr. William M. (Obi) Greenman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Jami K. Nachtsheim ,
Jami K. Nachtsheim ,
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Product
52.45M
0.00%
By RegionUSD
Name
Revenue
Proportion
North America
35.29M
67.28%
Europe and Middle East and Africa
16.61M
31.68%
Other
547.00K
1.04%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product
52.45M
0.00%
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
10.02%
BlackRock Institutional Trust Company, N.A.
8.05%
Baker Bros. Advisors LP
6.72%
The Vanguard Group, Inc.
5.61%
Wasatch Global Investors Inc
4.45%
Other
65.14%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
10.02%
BlackRock Institutional Trust Company, N.A.
8.05%
Baker Bros. Advisors LP
6.72%
The Vanguard Group, Inc.
5.61%
Wasatch Global Investors Inc
4.45%
Other
65.14%
Shareholder Types
Shareholders
Proportion
Investment Advisor
30.99%
Investment Advisor/Hedge Fund
22.61%
Hedge Fund
16.35%
Individual Investor
4.68%
Research Firm
2.33%
Family Office
1.27%
Bank and Trust
0.10%
Pension Fund
0.07%
Venture Capital
0.06%
Other
21.54%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
297
139.12M
72.57%
-10.92M
2025Q2
331
150.59M
78.56%
-11.76M
2025Q1
349
154.49M
80.95%
-4.85M
2024Q4
362
150.65M
81.09%
-18.33M
2024Q3
373
152.20M
82.15%
-11.01M
2024Q2
387
150.50M
81.41%
-12.83M
2024Q1
386
146.19M
80.62%
-12.96M
2023Q4
385
141.79M
78.32%
-24.31M
2023Q3
382
146.35M
81.02%
-13.17M
2023Q2
384
145.73M
80.79%
-19.32M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
19.21M
10.02%
-1.45M
-7.01%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
15.43M
8.05%
+2.50M
+19.30%
Jun 30, 2025
Baker Bros. Advisors LP
12.88M
6.72%
-6.47M
-33.42%
Jun 30, 2025
The Vanguard Group, Inc.
10.72M
5.59%
+168.09K
+1.59%
Jun 30, 2025
Wasatch Global Investors Inc
8.53M
4.45%
+213.92K
+2.57%
Jun 30, 2025
Amova Asset Management Co., Ltd.
6.07M
3.17%
-121.05K
-1.96%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.35M
2.27%
-193.16K
-4.25%
Jun 30, 2025
BlackRock Financial Management, Inc.
4.16M
2.17%
+2.94M
+242.32%
Jun 30, 2025
Senvest Management, LLC
4.01M
2.09%
-400.00K
-9.08%
Jun 30, 2025
State Street Investment Management (US)
3.83M
2%
+32.39K
+0.85%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
ARK Genomic Revolution ETF
0.92%
Invesco NASDAQ Future Gen 200 ETF
0.59%
ARK Innovation ETF
0.24%
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.05%
iShares US Small-Cap Equity Factor ETF
0.04%
iShares Russell 2000 Growth ETF
0.02%
Proshares Ultra Russell 2000
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
View more
ARK Genomic Revolution ETF
Proportion0.92%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.59%
ARK Innovation ETF
Proportion0.24%
iShares Micro-Cap ETF
Proportion0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.05%
Fidelity Enhanced Small Cap ETF
Proportion0.05%
iShares US Small-Cap Equity Factor ETF
Proportion0.04%
iShares Russell 2000 Growth ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
